Drug intelligence / Profile preview

lente insulin + regular insulin

Development stage
Discontinued
Lead developer
Novo Nordisk
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Lente insulin + regular insulin is a combination of two types of insulins used historically to manage blood glucose in diabetes mellitus. Lente insulin (also known as "insulin zinc suspension") is an intermediate-acting form derived from porcine and bovine sources, combined with zinc to prolong its action. It has an onset of 1–2 hours, peaks at 8–12 hours, and can last over 24 hours. Regular insulin is a short-acting human or animal-derived preparation with an onset of about 30 minutes and duration up to 6–8 hours. The combination was designed to provide both immediate (regular) and sustained (lente) glycemic control by mimicking basal and prandial endogenous insulin secretion patterns. Both act by binding the Insulin receptor on target tissues, promoting glucose uptake from the bloodstream into cells, thus lowering blood sugar levels. Lente insulins have been discontinued for human use in most countries due to the advent of more predictable recombinant human insulins and analogs[3].

Other names
insulin zinc suspension + regular insulinlente/regular combination
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on lente insulin + regular insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lente insulin + regular insulin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call